# Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

> **NCT01072357** · PHASE1,PHASE2 · COMPLETED · sponsor: **Reza Dana, MD** · enrollment: 30 (actual)

## Conditions studied

- Corneal Neovascularization
- Corneal Graft Failure

## Interventions

- **DRUG:** Avastin® (bevacizumab)
- **DRUG:** 0.9% NaCl & Refresh Liquigel

## Key facts

- **NCT ID:** NCT01072357
- **Lead sponsor:** Reza Dana, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072357, "Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01072357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*